BMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $75.00 (from $70.00) while maintaining a Outperform rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Ionis Pharma (IONS) Highlights Top-Line Data from Phase 1/2 Study of ONIS-HTTRx (RG6042) at AAN MeetingsApril 24, 2018 12:17 PM Biogen boosts investment in neurology with $1 billion Ionis dealApril 20, 2018 8:04 AM Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug DevelopmentApril 20, 2018 6:37 AM Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological DiseasesApril 20, 2018 6:30 AM